Xencor, Inc. (NASDAQ:XNCR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday.

According to Zacks, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. “

Other research analysts also recently issued research reports about the stock. Canaccord Genuity reaffirmed a “buy” rating and issued a $36.00 target price on shares of Xencor in a research report on Tuesday, August 8th. Piper Jaffray Companies reissued a “buy” rating and issued a $35.00 price objective on shares of Xencor in a research report on Sunday, November 12th. ValuEngine downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research report on Monday, October 23rd. Finally, BidaskClub downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the stock. Xencor has an average rating of “Hold” and a consensus target price of $30.25.

Xencor (NASDAQ:XNCR) opened at $21.66 on Wednesday. Xencor has a 12-month low of $18.55 and a 12-month high of $29.38.

COPYRIGHT VIOLATION WARNING: “Xencor, Inc. (XNCR) Lifted to Hold at Zacks Investment Research” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.watchlistnews.com/xencor-inc-xncr-lifted-to-hold-at-zacks-investment-research/1719315.html.

In related news, major shareholder John S. Stafford III bought 3,400 shares of the business’s stock in a transaction dated Wednesday, November 8th. The stock was bought at an average price of $19.89 per share, for a total transaction of $67,626.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder John S. Stafford III bought 24,653 shares of the business’s stock in a transaction dated Wednesday, October 25th. The shares were bought at an average price of $20.01 per share, with a total value of $493,306.53. The disclosure for this purchase can be found here. In the last three months, insiders bought 242,382 shares of company stock valued at $4,795,353. Insiders own 4.14% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC lifted its stake in shares of Xencor by 77.7% during the 2nd quarter. FMR LLC now owns 6,690,258 shares of the biopharmaceutical company’s stock worth $141,232,000 after buying an additional 2,924,510 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Xencor by 5.6% during the 2nd quarter. Vanguard Group Inc. now owns 1,701,209 shares of the biopharmaceutical company’s stock worth $35,913,000 after buying an additional 90,094 shares during the last quarter. State Street Corp lifted its stake in shares of Xencor by 11.1% during the 2nd quarter. State Street Corp now owns 1,103,455 shares of the biopharmaceutical company’s stock worth $23,295,000 after buying an additional 110,474 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Xencor by 6.6% during the 2nd quarter. Northern Trust Corp now owns 498,616 shares of the biopharmaceutical company’s stock worth $10,527,000 after buying an additional 30,715 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Xencor by 8.0% during the 1st quarter. Geode Capital Management LLC now owns 367,230 shares of the biopharmaceutical company’s stock worth $8,783,000 after buying an additional 27,099 shares during the last quarter. Institutional investors own 76.97% of the company’s stock.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.